QIAGEN Debt to Equity Ratio 2010-2023 | QGEN
Current and historical debt to equity ratio values for QIAGEN (QGEN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. QIAGEN debt/equity for the three months ending March 31, 2023 was 0.42.
| QIAGEN Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-03-31 |
$2.72B |
$3.56B |
0.76 |
| 2022-12-31 |
$2.82B |
$3.47B |
0.81 |
| 2022-09-30 |
$3.19B |
$3.33B |
0.96 |
| 2022-06-30 |
$2.87B |
$3.28B |
0.88 |
| 2022-03-31 |
$2.94B |
$3.24B |
0.91 |
| 2021-12-31 |
$3.05B |
$3.10B |
0.99 |
| 2021-09-30 |
$3.03B |
$3.01B |
1.01 |
| 2021-06-30 |
$2.93B |
$2.98B |
0.98 |
| 2021-03-31 |
$2.91B |
$2.85B |
1.02 |
| 2020-12-31 |
$3.07B |
$2.80B |
1.10 |
| 2020-09-30 |
$3.06B |
$2.71B |
1.13 |
| 2020-06-30 |
$2.67B |
$2.62B |
1.02 |
| 2020-03-31 |
$2.69B |
$2.49B |
1.08 |
| 2019-12-31 |
$2.70B |
$2.54B |
1.06 |
| 2019-09-30 |
$2.68B |
$2.47B |
1.08 |
| 2019-06-30 |
$2.75B |
$2.63B |
1.05 |
| 2019-03-31 |
$2.81B |
$2.61B |
1.08 |
| 2018-12-31 |
$3.11B |
$2.64B |
1.18 |
| 2018-09-30 |
$2.77B |
$2.53B |
1.10 |
| 2018-06-30 |
$2.79B |
$2.52B |
1.10 |
| 2018-03-31 |
$2.53B |
$2.58B |
0.98 |
| 2017-12-31 |
$2.50B |
$2.54B |
0.98 |
| 2017-09-30 |
$2.53B |
$2.57B |
0.99 |
| 2017-06-30 |
$2.05B |
$2.51B |
0.82 |
| 2017-03-31 |
$1.64B |
$2.43B |
0.67 |
| 2016-12-31 |
$1.70B |
$2.61B |
0.65 |
| 2016-09-30 |
$1.66B |
$2.67B |
0.62 |
| 2016-06-30 |
$1.49B |
$2.63B |
0.57 |
| 2016-03-31 |
$1.50B |
$2.63B |
0.57 |
| 2015-12-31 |
$1.61B |
$2.57B |
0.63 |
| 2015-09-30 |
$1.64B |
$2.52B |
0.65 |
| 2015-06-30 |
$1.59B |
$2.54B |
0.63 |
| 2015-03-31 |
$1.69B |
$2.48B |
0.68 |
| 2014-12-31 |
$1.80B |
$2.66B |
0.68 |
| 2014-09-30 |
$1.75B |
$2.71B |
0.64 |
| 2014-06-30 |
$1.81B |
$2.76B |
0.66 |
| 2014-03-31 |
$1.75B |
$2.73B |
0.64 |
| 2013-12-31 |
$1.37B |
$2.72B |
0.50 |
| 2013-09-30 |
$1.38B |
$2.68B |
0.52 |
| 2013-06-30 |
$1.38B |
$2.60B |
0.53 |
| 2013-03-31 |
$1.34B |
$2.69B |
0.50 |
| 2012-12-31 |
$1.36B |
$2.72B |
0.50 |
| 2012-09-30 |
$1.25B |
$2.71B |
0.46 |
| 2012-06-30 |
$1.24B |
$2.64B |
0.47 |
| 2012-03-31 |
$1.16B |
$2.64B |
0.44 |
| 2011-12-31 |
$1.17B |
$2.56B |
0.46 |
| 2011-09-30 |
$1.36B |
$2.59B |
0.53 |
| 2011-06-30 |
$1.40B |
$2.59B |
0.54 |
| 2011-03-31 |
$1.42B |
$2.54B |
0.56 |
| 2010-12-31 |
$1.44B |
$2.48B |
0.58 |
| 2010-09-30 |
$1.46B |
$2.43B |
0.60 |
| 2010-06-30 |
$1.43B |
$2.34B |
0.61 |
| 2010-03-31 |
$1.47B |
$2.31B |
0.64 |
| 2009-12-31 |
$1.51B |
$2.29B |
0.66 |
| 2009-09-30 |
$1.53B |
$2.23B |
0.69 |
| 2009-06-30 |
$1.44B |
$1.54B |
0.94 |
| 2009-03-31 |
$1.37B |
$1.46B |
0.94 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.491B |
$2.142B |
|
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
|
